We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Carolina Liquid Chemistries and Diazyme Enter Into Partnership

By LabMedica International staff writers
Posted on 24 Jan 2023

Carolina Liquid Chemistries, Corp. (CLC, Greensboro, NC, USA) and Diazyme Laboratories, Inc. (San Diego, CA, USA) have entered into a partnership to expand the test menu on the Diazyme DZ-Lite c270 benchtop clinical chemistry analyzer, allowing it to run both special and routine chemistries.

In comparison to using time-consuming and labor-intensive immunoassay platforms, it is more economical to run tests on clinical chemistry analyzers. The DZ-Lite c270 is an advanced benchtop clinical chemistry analyzer with a menu of FDA-cleared, moderately complex, and innovative assays made for clinical laboratories of all sizes. The compact clinical chemistry analyzer supports 1, 2, 3, and 4-part reagent assays and has a throughput of up to 270 tests per hour. The analyzer can be used in all types of clinical laboratory settings such as reference laboratories, hospitals, and physician offices with clinical labs.


Image: DZ-Lite c270 Benchtop Chemistry Analyzer (Photo courtesy of Carolina Liquid Chemistries)
Image: DZ-Lite c270 Benchtop Chemistry Analyzer (Photo courtesy of Carolina Liquid Chemistries)

Related Links:
Carolina Liquid Chemistries, Corp. 
Diazyme Laboratories, Inc


New
Gold Member
Aspiration System
VACUSAFE
Online QC Software
Acusera 24•7
New
HPV Molecular Test
BD Onclarity HPV Assay
New
Total Laboratory Automation Solution
SATLARS Mini T8

Latest Industry News

Roche to Acquire PathAI for Up to $1.05 Billion to Strengthen AI Diagnostics Portfolio
24 Jan 2023  |   Industry

FDA Clears Blood-Based Companion Diagnostic for Advanced Breast Cancer Therapy
24 Jan 2023  |   Industry

CareDx Expands Precision Oncology Portfolio with Naveris Acquisition
24 Jan 2023  |   Industry



ADLM